HCPLive Network

Promising Results for First Pharmacologic Treatment for Celiac Disease

 
Larazotide acetate 0.5 mg has the potential to be the first pharmacologic treatment for celiac disease, a genetic autoimmune condition affecting 1% of the western population.
 
Treatment with larazotide acetate 0.5 mg three times a day reduced GI and non-GI symptoms in a study of more than 800 patients while also reducing the number of symptomatic days (the days on which patients reported significant symptoms) by 26% through the duration of the study, an effect not seen at higher doses.
 
Conversely, treatment with larazotide acetate 0.5 mg increased by 31% the number of days patients reported few to no symptoms.
 
The safety and tolerability profile of Larazotide acetate was comparable to placebo. No treatment-related serious adverse events were reported.
 
This study represents the first large therapeutic trial in celiac disease to meet its primary endpoint of reducing signs and symptoms of celiac disease and is the first successful trial of a novel class of agents targeting Tight Junctions regulation, according to Joseph Murray, MD, with Mayo Clinic.
 
In the study, the large majority of participants were women (mean age 45 years) who had been on a gluten-free diet for an average of 5 years, so they were patients experienced with managing their disease and treatment.
 
Larazotide acetate also significantly reduced non-GI symptoms such as headache and tiredness commonly reported by celiac patients.
 
Because it is triggered by ingesting gluten, celiac disease is usually managed by a lifetime gluten-free diet. But up to 72% of people with celiac disease have recurrent symptoms from inadvertent exposure to gluten in foods or everyday products (such as medicines, vitamins, lip balm, etc) or straying from their gluten-free diet.
 
In addition to affecting quality of life, the disease comes with increased risk of GI cancers and T-cell lymphoma.
 
“Celiac disease represents a significant unmet medical need,” Murray said. “It is increasing in prevalence worldwide and there is no standardized measure of response to therapy to conduct clinical trials.”
 
The primary endpoint of the study was reduction of GI symptoms using the celiac disease-specific domains of the GSRS (Gastrointestinal Symptom Rating Scale) includingdiarrhea, indigestion, and abdominal pain at the dose of 0.5 mg. This response was sustained through the active phase of the study, Murray said.
 
Treatment with larazotide acetate 1 mg and 2 mg was not effective, Murray said. “That’s consistent with all of the clinical challenge studies done previously. It was always the lowest dose used that was the most effective,” he said.
 
In light of these positive trial results, Murray said larazotide acetate 0.5 mg warrants further investigation in phase III clinical trials.
 
 

Further Reading
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.
Daily supplements of selenium or vitamin E don't seem to protect against the development of age-related cataracts among men, according to a study published online Sept. 18 in JAMA Ophthalmology.
Workplace flu shots are a good investment, a new survey found. The US Centers for Disease Control and Prevention (CDC) on Sept. 19 urged all health care personnel to get flu vaccinations. The CDC also released the results of a survey of 1,882 health care clinicians meant to determine what factors influenced those who got the shots. Among its findings, when workplaces offered free shots on-site, compliance was 61.6% when the vaccinations were offered for one day only. When they were offered for multiple days, compliance rose to 80.4%. When employers did not offer the shots at all, compliance dropped to 49.0%
Cancer patients burdened by stress and family conflicts before surgery may face a higher risk for complications following their operation, according to a study published in a recent issue of the Journal of Gastrointestinal Surgery.
President Barack Obama escalated the fight against antibiotic-resistant bacteria on Thursday, ordering key federal agencies to pursue a national strategy to deal with the threat.
The US Centers for Disease Control and Prevention have released a Category A recommendation for revised routine pneumococcal vaccination in older adults. The recommendation has been published in the Sept. 19 issue of the CDC's Morbidity and Mortality Weekly Report.
The presence of other health care workers improves hand hygiene adherence, according to a study published in the October issue of Infection Control and Hospital Epidemiology.
More Reading
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.